Pexacerfont
Pexacerfont, also known as BMS-562086, is a potent and orally active CRF-1 antagonist. Pexacerfont is a recently developed CRF-1 antagonist which is currently in clinical trials for the treatment of anxiety disorders, and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome. BMS-562086 exhibited favorable ADME and pharmacokinetic properties for further development.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD339 |
| CAS # | 459856-18-9 |
| Pricing | Customizable size, Inquiry |
| Synonym | BMS-562086; BMS 562086; BMS562086; BMS-562,086; BMS562,086; BMS 562,086; Pexacerfont. |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C18H24N6O |
| Exact Mass | 340.2012 |
| Molecular Weight | 340.431 |
| Elemental Analysis | C, 63.51; H, 7.11; N, 24.69; O, 4.70 |
| IUPAC/Chemical Name | 8-(6-Methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-((1R)-1-methylpropyl)pyrazolo(1,5-a)-1,3,5-triazin-4-amine |
| InChi Key | LBWQSAZEYIZZCE-SNVBAGLBSA-N |
| InChi Code | InChI=1S/C18H24N6O/c1-7-10(2)19-18-22-13(5)21-17-16(12(4)23-24(17)18)14-8-9-15(25-6)20-11(14)3/h8-10H,7H2,1-6H3,(H,19,21,22)/t10-/m1/s1 |
| SMILES Code | CC[C@H](NC1=NC(C)=NC2=C(C3=CC=C(OC)N=C3C)C(C)=NN21)C |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO, not in water |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |